Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 4/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.59 |
| ▸ | KDR | P35968 | 7/20 | 0.58 |
| ▸ | KIT | P10721 | 6/20 | 0.58 |
| ▸ | FLT3 | P36888 | 5/20 | 0.58 |
| ▸ | JAK2 | O60674 | 5/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.54 |
| ▸ | LCK | P06239 | 3/20 | 0.54 |
| ▸ | CSF1R | P07333 | 3/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.54 |
| ▸ | PRKACA | P17612 | 3/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.54 |
| ▸ | PLK4 | O00444 | 2/20 | 0.54 |
| ▸ | AURKA | O14965 | 2/20 | 0.54 |
| ▸ | CDK1 | P06493 | 2/20 | 0.54 |
| ▸ | LYN | P07948 | 2/20 | 0.54 |
| ▸ | SRC | P12931 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30065304 | 1.00 | PDPK1 (0.66) | PDPK1GAAMAP2K1KDRKIT | |
| SCHEMBL1172394 | 0.79 | GAA (0.56) | PDPK1GAAMAP2K1KDRKIT | |
| SCHEMBL10076075 | 0.79 | KDR (0.47) | PDPK1GAAMAP2K1KDRKIT | |
| SCHEMBL7736987 | 0.79 | PDPK1 (0.61) | PDPK1GAAMAP2K1KDRKIT | |
| SCHEMBL186280 | 0.79 | GAA (1.00) | PDPK1GAAMAP2K1KDRKIT | |
| SCHEMBL10368038 | 0.79 | PDPK1 (0.61) | PDPK1GAAMAP2K1KDRKIT | |
| SCHEMBL185907 | 0.79 | GAA (0.61) | PDPK1GAAMAP2K1KDRKIT | |
| SCHEMBL1172460 | 0.79 | GAA (0.47) | PDPK1GAAMAP2K1KDRKIT | |
| SCHEMBL12928484 | 0.79 | PDPK1 (0.61) | PDPK1GAAMAP2K1KDRKIT | |
| SCHEMBL760018 | 0.79 | PDPK1 (0.61) | PDPK1GAAMAP2K1KDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1820503-B1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA SRL (IT) | 2012-02-22 | — | — | EP | claimed |
| EP-1432416-B1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER ITALIA SRL (IT) | 2011-01-19 | — | — | EP | claimed |
| WO-2010059658-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | claimed |
| CN-108786619-B | Bone material dispensing apparatus and method | 华沙整形外科股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| WO-2021093795-A1 | ROCK INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉朗来科技发展有限公司 | 2021-05-20 | — | — | WO | disclosed |
| EP-2182914-B1 | COMPOSITION OXIDATION COLOURING OF KERATINIC FIBRES, CONTAINING A CATIONIC CELLULOSE ETHER, A METASILICATE AND OXIDATION DYES, METHOD FOR OXIDATION COLOURING AND USES THEREOF | L'ORÉAL (FR) | 2017-11-08 | — | — | EP | disclosed |
| WO-2017045751-A1 | COMPOUNDS AS ASIC INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| US-20160297833-A1 | THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS | Bayer Pharma AG (DE) | 2016-10-13 | — | — | US | disclosed |
| EP-3071577-A1 | THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015074986-A1 | THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | WO | disclosed |
| EP-1487804-B1 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2014-02-26 | — | — | EP | disclosed |
| EP-1537087-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2005-06-08 | — | — | EP | disclosed |
| EP-1487804-A2 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | disclosed |
| EP-1459732-A1 | Dye composition comprising at least one heterocyclic oxidation base and at least one 2,3,5-triaminopyridine as coupler | L'OREAL (FR) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004062662-A1 | AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-07-29 | — | — | WO | disclosed |
| EP-1413286-A1 | Dyeing composition comprising at least one heterocyclic oxidation base and at least one substituted 2,3-diaminopyridine as a coupling agent | L'OREAL (FR) | 2004-04-28 | — | — | EP | disclosed |
| WO-2004022544-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004009557-A1 | 6-AMINO-1H-INDAZOLE AND 4-AMINOBENZOFURAN COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2003078403-A2 | DERIVES D’AMINOINDAZOLES COMME INHIBITEURS DE PROTEINE-KINASE | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | disclosed |
| EP-0904769-B1 | Keratin fibre dye compositions containing Indazole amine derivatives and dyeing method | OREAL (FR) | 2002-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297833-A1 | THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS | MKNK1, MKNK2, DTYMK | PDPK1 77/4885GAA 2053/4885MAP2K1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.